Late diagnosis, delayed presentation and late presentation in HIV: Proposed definitions, methodological considerations and health implications

Antiviral Therapy

Volumn 18, Issue 1, 2013, Pages 17-23

  Kozak, Michael ^a   Zinski, Anne ^a   Leeper, Connie ^a   Willig, James H ^a   Mugavero, Michael J ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BRONCHOSCOPY; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; DELAYED DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTEGRATED HEALTH CARE SYSTEM; LYMPHADENOPATHY; MEDICAL CARE; NONHUMAN; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; PUBLIC HEALTH SERVICE; REVIEW; THERAPY DELAY; VIRUS LOAD; WESTERN BLOTTING;

DELAYED DIAGNOSIS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PUBLIC HEALTH; RISK FACTORS;

EID: 84874418965     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2534     Document Type: Review

References (37)

1. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52:793-800.
2. Centers for Disease Control and Prevention. Vital signs: HIV prevention through care and treatment-United States. MMWR Morb Mortal Wkly Rep 2011; 60:1618-1623.
3. Campsmith ML, Rhodes PH, Hall HI, Green TA. Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr 2010; 53:619-624.
4. Boulos D, Yan P, Schanzer D, Remis RS, Archibald CP. Estimates of HIV prevalence and incidence in Canada, 2005. Can Commun Dis Rep 2006; 32:165-174.
5. Hamers FF, Phillips AN. Diagnosed and undiagnosed HIV-infected populations in Europe. HIV Med 2008; 9 Suppl 2:6-12.
6. Adler A, Mounier-Jack S, Coker RJ. Late diagnosis of HIV in Europe: Definitional and public health challenges. AIDS Care 2009; 21:284-293.
7. Johnson M, Sabin C, Girardi E. Definition and epidemiology of late presentation in Europe. Antivir Ther 2010; 15 Suppl 1:3-8.
8. Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA 2009; 301:2380-2382.
9. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
10. Girardi E, Sabin CA, Monforte AD. Late diagnosis of HIV infection: Epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr 2007; 46 Suppl 1:S3-S8.
11. Antinori A, Coenen T, Costagiola D, et al. Late presentation of HIV infection: A consensus definition. HIV Med 2011; 12:61-64.
12. Cavassini M, Elzi L. Late diagnosis of HIV: A trigger to change our practice? European Infectious Diseases 2008; 2:35-38.
13. Krawczyk CS, Funkhouser E, Kilby JM, Vermund SH. Delayed access to HIV diagnosis and care: Special concerns for the Southern United States. AIDS Care 2006; 18 Suppl 1:S35-S44.
14. Girardi E, Aloisi MS, Arici C, et al. Delayed presentation and late testing for HIV: Demographic and behavioral risk factors in a multicenter study in Italy. J Acquir Immune Defic Syndr 2004; 36:951-959.
15. Ndiaye B, Salleron J, Vincent A, et al. Factors associated with presentation to care with advanced HIV disease in Brussels and Northern France: 1997-2007. BMC Infect Dis 2011; 11:11.
16. Chadborn TR, Delpech VC, Sabin CA, Sinka K, Evans BG. The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS 2006; 20:2371-2379.
17. Samet JH, Freedberg KA, Stein MD, et al. Trillion virion delay: Time from testing positive for HIV to presentation for primary care. Arch Intern Med 1998; 158:734-740.
18. The White House Office on National AIDS Policy. National HIV/AIDS strategy for the United States. (Updated July 2010. Accessed 14 May 2012.) Available from http://www. whitehouse.gov/sites/default/files/uploads/NHAS.pdf
19. Centers for Disease Control and Prevention. HIV prevention strategic plan: Extended through 2010. (Updated October 2007. Accessed 14 May 2012.) Available from http://www. cdc.gov/hiv/resources/reports/psp/pdf/psp.pdf
20. Sabin CA, Schwenk A, Johnson MA, et al. Late diagnosis in the HAART era: Proposed common definitions and associations with mortality. AIDS 2010; 24:723-727.
21. Nakashima AK, Campsmith ML, Wolfe MI, Nakamura G, Begley EB. Late versus early testing of HIV-16 sites, United States, 2000-2003. MMWR Morb Mortal Wkly Rep 2003; 52:581-586.
22. McCoy SI, Jones B, Leone PA, et al. Variability of the date of HIV diagnosis: A comparison of self-report, medical record, and HIV/AIDS surveillance data. Ann Epidemiol 2010; 20:734-742.
23. Hall HI, Li J, Campsmith M, Sweeny P, Lee LM. Date of first positive HIV test: Reliability of information collected for HIV/AIDS surveillance in the United States. Public Health Rep 2005; 120:89-95.
24. Fairchild AL, Bayer R. HIV surveillance, public health, and clinical medicine-will the walls come tumbling down? N Engl J Med 2011; 365:685-687.
25. Zetola NM, Bernstein K, Ahrens K, et al. Using surveillance data to monitor entry into care of newly diagnosed HIVinfected persons: San Francisco, 2006-2007. BMC Public Health 2009; 9:17.
26. Tripathi A, Youmans E, Gibson JJ, Duffus WA. The impact of retention in early HIV medical care on viroimmunological parameters and survival: A statewide study. AIDS Res Hum Retroviruses 2011; 27:751-758.
27. Gandhi NR, Skanderson M, Gordon KS, Concato J, Justice AC. Delayed presentation for human immunodeficiency virus (HIV) care among veterans: A problem of access or screening? Med Care 2007; 45:1105-1109.
28. Burkey MD, Wilson LE, Moore RD, Lucas GM, Francis J, Gebo KA. The incidence of and risk factors for MRSA bacteraemia in an HIV-infected cohort in the HAART era. HIV Med 2008; 9:858-862.
29. Lanoy E, Mary-Krause M, Tattevin P, et al. Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir Ther 2007; 12:89-96.
30. Kelley CF, Kitchen CM, Hunt PW, et al. Incomplete peripheral CD4+ T-cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 2009; 48:787-794.
31. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
32. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-299.
33. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Metaanalysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: Implications for HIV prevention programs. J Acquir Immune Defic Syndr 2005; 39:446-453.
34. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929.
35. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS ONE 2010; 5:e11068.
36. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4 <200 cells/microL) with HIV infection. HIV Med 2004; 5:93-98.
37. Fleishman JA, Yehia BR, Moore RD, Gebo KA. The economic burden of late entry into medical care for patients with HIV infection. Med Care 2010; 48:1071-1079.